Diethylpropion HCl, like many anti-obesity drugs, is primarily sold to bariatric clinics, the company said.
Lannett president and CEO Arthur P Bedrosian said the approval would add to their line of anti-obesity medications.
"Our pipeline remains deep, with a number of ANDAs currently pending at the FDA, several of which we expect to be approved over the next couple of quarters," Bedrosian added.